Aktie 4162 PHARMAENGINE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen PharmaEngine, Inc.

Aktien

4162

TW0004162003

4162

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 09.05.2024 		% 5 Tage % 1. Jan.
93,3 TWD -0,74 % Intraday Chart für PharmaEngine, Inc. -0,43 % -11,56 %
02.05. PharmaEngine, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
24.04. PharmaEngine, Inc. gibt die Verabreichung des ersten Patienten in der Phase-I-Studie mit PEP07 bei soliden Tumoren bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors
PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
PharmaEngine, Inc. Announces Consolidated Revenue Results for the Month and Year Ended December 2023
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of Pep07 for Hematological Cancers
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
PharmaEngine, Inc. Announces Dividend, Payable on September 1, 2023
PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application
PharmaEngine, Inc. Files Post-Approval Change Application for A New Indication of ONIVYDE to TFDA
PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Australia HREC Approves and Australia TGA Acknowledges PharmaEngine, Inc.'s Phase 1 Clinical Study of PEP07
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
PharmaEngine, Inc. Announces Change of Board of Directors Chairperson
PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 4162 Aktie
  4. Nachrichten PharmaEngine, Inc.
  5. Andere Sprachen